Advanced in Urothelial Cancer

Dr. Dan Sotirescu

Hematology Oncology
UPMC
Cancer Care Associates Of York
25 Monument Road, Suite 294, 
York, PA 
On Staff At
Offers Telehealth
Advanced in Urothelial Cancer
UPMC
Cancer Care Associates Of York
25 Monument Road, Suite 294, 
York, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dan Sotirescu is a Hematologist Oncology provider in York, Pennsylvania. Dr. Sotirescu is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Severe Congenital Neutropenia, Lung Cancer, Pleuropulmonary Blastoma, Multiple Myeloma, and Bone Marrow Aspiration.

His clinical research consists of participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in PA
Fellowships
University of Maryland Medical Center
Hospital Affiliations
Wellspan York Hospital
Gettysburg Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Cancer Care Associates of York
25 Monument Road, Suite 294, York, PA 17403
Call: 717-741-9229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
Evaluation of Mammographic Breast Density Effect of Aspirin: a Companion Study to Alliance Study A011502
Evaluation of Mammographic Breast Density Effect of Aspirin: a Companion Study to Alliance Study A011502
Enrollment Status: Terminated
Publish Date: January 16, 2025
Intervention Type: Procedure
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Enrollment Status: Unknown
Publish Date: October 15, 2021
Intervention Type: Other, Drug
Study Drugs: Palbociclib, Letrozole, Fulvestrant
Study Phase: Phase 2
View 10 Less Clinical Trials
Similar Doctors
Elite in Urothelial Cancer
Dr. Monika D. Joshi
Hematology Oncology | Hematology | Oncology
Elite in Urothelial Cancer
Dr. Monika D. Joshi
Hematology Oncology | Hematology | Oncology

The Milton S Hershey Medical Center Physicians Group

500 University Dr, 
Hershey, PA 
 (23.6 miles away)
717-531-8395
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Monika Joshi is a Hematologist Oncology specialist and a Hematologist in Hershey, Pennsylvania. Dr. Joshi is rated as a Distinguished provider by MediFind in the treatment of Urothelial Cancer. Her top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Renal Cell Carcinoma (RCC), and Bone Marrow Aspiration.

Distinguished in Urothelial Cancer
Dr. Chanh T. Huynh
Hematology Oncology | Hematology | Oncology
Distinguished in Urothelial Cancer
Dr. Chanh T. Huynh
Hematology Oncology | Hematology | Oncology

Cancer Care Associates Of York, Inc.

25 Monument Rd, Suite 294, 
York, PA 
 (0.3 miles away)
717-741-9229
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Chanh Huynh is a Hematologist Oncology specialist and a Hematologist in York, Pennsylvania. Dr. Huynh is rated as a Distinguished provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Colorectal Cancer, Lynch Syndrome, Familial Colorectal Cancer, and Bone Marrow Aspiration.

Distinguished in Urothelial Cancer
Dr. Dhaval R. Shah
Hematology Oncology | Hematology | Oncology
Distinguished in Urothelial Cancer
Dr. Dhaval R. Shah
Hematology Oncology | Hematology | Oncology

Medical Oncology Hematology Consultants PA

4701 Ogletown Stanton Rd, Suite 3400, 
Newark, DE 
 (57.5 miles away)
302-366-1200
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Dhaval Shah is a Hematologist Oncology specialist and a Hematologist in Newark, Delaware. Dr. Shah is rated as a Distinguished provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Urothelial Cancer, Large-Cell Immunoblastic Lymphoma, and Bone Marrow Aspiration. Dr. Shah is currently accepting new patients.

VIEW MORE UROTHELIAL CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sotirescu's expertise for a condition
ConditionClose
    • Distinguished
    • Agranulocytosis
      Dr. Sotirescu is
      Distinguished
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Childhood Iron Deficiency Anemia
      Dr. Sotirescu is
      Distinguished
      . Learn about Childhood Iron Deficiency Anemia.
      See more Childhood Iron Deficiency Anemia experts
    • Chronic Familial Neutropenia
      Dr. Sotirescu is
      Distinguished
      . Learn about Chronic Familial Neutropenia.
      See more Chronic Familial Neutropenia experts
    • Lung Cancer
      Dr. Sotirescu is
      Distinguished
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    • Melanoma
      Dr. Sotirescu is
      Distinguished
      . Learn about Melanoma.
      See more Melanoma experts
    • Multiple Myeloma
      Dr. Sotirescu is
      Distinguished
      . Learn about Multiple Myeloma.
      See more Multiple Myeloma experts
    View All 11 Distinguished Conditions
    • Advanced
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Sotirescu is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Angiosarcoma
      Dr. Sotirescu is
      Advanced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Breast Cancer
      Dr. Sotirescu is
      Advanced
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Chronic B-Cell Leukemia (CBCL)
      Dr. Sotirescu is
      Advanced
      . Learn about Chronic B-Cell Leukemia (CBCL).
      See more Chronic B-Cell Leukemia (CBCL) experts
    • Chronic Lymphocytic Leukemia (CLL)
      Dr. Sotirescu is
      Advanced
      . Learn about Chronic Lymphocytic Leukemia (CLL).
      See more Chronic Lymphocytic Leukemia (CLL) experts
    • Dehydration
      Dr. Sotirescu is
      Advanced
      . Learn about Dehydration.
      See more Dehydration experts
    View All 29 Advanced Conditions
    • Experienced
    • Acute Monoblastic Leukemia (AmoL)
      Dr. Sotirescu is
      Experienced
      . Learn about Acute Monoblastic Leukemia (AmoL).
      See more Acute Monoblastic Leukemia (AmoL) experts
    • Acute Mountain Sickness
      Dr. Sotirescu is
      Experienced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Sotirescu is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Sotirescu is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Sotirescu is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Adult Soft Tissue Sarcoma
      Dr. Sotirescu is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    View All 123 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

        Close
        0 / 1000

        Please provide us with the below insurance information:

                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.